Heatwurx Inc. (NASDAQ:PCSA) Short Interest Update

Heatwurx Inc. (NASDAQ:PCSA) saw a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 67,319 shares, a decrease of 68.8% from the July 30th total of 215,851 shares. Based on an average trading volume of 78,571 shares, the short-interest ratio is presently 0.9 days. Currently, 2.5% of the company’s stock are sold short.

Heatwurx Trading Down 2.4%

Shares of PCSA traded down $0.05 on Friday, reaching $2.06. 9,591 shares of the company’s stock traded hands, compared to its average volume of 132,371. The stock’s 50 day simple moving average is $2.22 and its two-hundred day simple moving average is $2.46. The stock has a market cap of $5.71 million, a PE ratio of -0.49 and a beta of 0.99. Heatwurx has a 52-week low of $1.67 and a 52-week high of $14.24.

Heatwurx (NASDAQ:PCSA) last announced its earnings results on Friday, August 14th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.19).

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $25.00.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.